<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532463</url>
  </required_header>
  <id_info>
    <org_study_id>122020</org_study_id>
    <nct_id>NCT04532463</nct_id>
  </id_info>
  <brief_title>Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis</brief_title>
  <official_title>Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis in Patients With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pharmacy, Yangon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pharmacy, Yangon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole&#xD;
      therapy for cryptococcal meningitis in patients with HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cryptococcal meningitis is an AIDS-defining illness mostly caused by the fungus, Cryptococcus&#xD;
      neoformans. In high-income countries, the use of amphotericin B in combination with a more&#xD;
      expensive drug, flucytosine, is most effective for the management of cryptococcal meningitis;&#xD;
      but access to flucytosine is severely limited in middle and low-income countries. In Myanmar,&#xD;
      currently recommended regimen for cryptococcal meningitis are combination of amphotericin B&#xD;
      with fluconazole. Although amphotericin plus flucytosine followed by fluconazole therapy is&#xD;
      the currently preferred regimen in WHO treatment guidelines, it is not still commonly used in&#xD;
      Myanmar clinical practice because of its limited availability. Therefore, the data regarding&#xD;
      tolerability and clinical effectiveness of flucytosine are unavailable for Myanmar patients.&#xD;
&#xD;
      Although trials were carried out for investigating the effectiveness of flucytosine in the&#xD;
      HIV population of Africa, the variability in drug response can occur in Myanmar patients due&#xD;
      to the racial and genetic differences and whether it is effective and safe for Myanmar people&#xD;
      is a great curiosity question for clinicians and healthcare workers. In Myanmar, amphotericin&#xD;
      plus flucytosine followed by fluconazole regimen will be supplied by National AIDS Program&#xD;
      (NAP) and indicated in 2020. Thus, the documents for effectiveness and safety profile need to&#xD;
      be established. This is the reason that the effectiveness and safety of amphotericin B with&#xD;
      flucytosine and fluconazole combination therapy should be studied. From this study, it can&#xD;
      provide information to physicians regarding the effectiveness as well as safety of those&#xD;
      drugs in the management of cryptococcal meningitis in HIV patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical effectiveness</measure>
    <time_frame>14 days (day1 to day 14)</time_frame>
    <description>To describe the clinical effectiveness of amphotericin B with flucytosine-fluconazole combination therapy by assessing clinical parameters (presence of headache, fever, convulsion, abnormal mental status and death) at day 1, day 7 and day 14&#xD;
To determine the severity of headache before and after treatment by numerical rating scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical safety</measure>
    <time_frame>14 days (day1 to day 14)</time_frame>
    <description>3. . To describe the clinical safety of amphotericin B with flucytosine-fluconazole combination therapy by assessing hematological and biochemical parameters (hemoglobin, neutrophil, platelet, ALT, AST, serum creatinine and serum potassium level ) by DAIDS grading at baseline, day 7 and day 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>back-ground characteristics of patients</measure>
    <time_frame>14 days (day1 to day 14)</time_frame>
    <description>4. To find out the back-ground characteristics of patients (age,gender) with HIV-associated cryptococcal meningitis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>Amphotericin B,Flucytosine, Fluconazole</arm_group_label>
    <description>Amphotericin B 1 mg/kg 1 week &amp; Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B 1 mg/kg 1 week &amp; Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week</intervention_name>
    <description>To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.</description>
    <arm_group_label>Amphotericin B,Flucytosine, Fluconazole</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to SHW, SHM and SHT with HIV-associated cryptococcal meningitis who will&#xD;
        be treated with amphotericin + flucytosine + fluconazole induction regimen.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with HIV-associated cryptococcal meningitis, admitted to inpatient department&#xD;
             of SHW, SHM and SHT during the study period&#xD;
&#xD;
          2. Patients of both sexes&#xD;
&#xD;
          3. Age above 14 years&#xD;
&#xD;
          4. Patients or caregivers who will give informed consent to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zin win may, B.Pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Specialist Hospital Thakeyta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zin win may, B.Pharm</last_name>
    <phone>+959975506984</phone>
    <email>zinwinmay.pharmacist@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Specialist hospital Mingalardon,Thakeyta,Waibargi</name>
      <address>
        <city>Yangon</city>
        <zip>11181</zip>
        <country>Myanmar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zin Win May, B.Pharm</last_name>
      <phone>09975506984</phone>
      <email>zinwinmay.pharmacist@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zin May, B.Pharm</last_name>
      <phone>09250242630</phone>
      <email>huhulay.92@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zin Win May, B.Pharm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Myanmar</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pharmacy, Yangon</investigator_affiliation>
    <investigator_full_name>Ms. Zin Win May, Principal Investigator</investigator_full_name>
    <investigator_title>Clinical effectiveness and safety of Amphotericin B with Flucytosine-Fluconazole therapy for Cryptococcal meningitis in patients with HIV infection</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Flucytosine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04532463/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

